Payment overview · 2025
General Payments
$46.27
2 reported records · 2 companies
Healthcare provider profile · identity verified
David Wayne Spinks, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PASADENA, TX · NPI 1972544500
Verified facts
What the public records show
CMS Open Payments records show David Wayne Spinks, D.O. received $46.27 in general payments during 2025 across 2 reported records.
Amgen Inc. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.04 | 54.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.23 | 45.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.27 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acetaminophen-Codeine | Acetaminophen With Codeine | 214 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 65 |
| Tramadol Hcl | Tramadol Hcl | 194 | 48 |
| Lisinopril | Lisinopril | 189 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 180 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 55 |
| Alprazolam | Alprazolam | 172 | 19 |
| Gabapentin | Gabapentin | 170 | 53 |
| Losartan Potassium | Losartan Potassium | 164 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 51 |
| Furosemide | Furosemide | 141 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 22 |
| Metformin Hcl | Metformin Hcl | 102 | 33 |
| Lorazepam | Lorazepam | 96 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 29 |
| Fenofibrate | Fenofibrate | 84 | 25 |
| Diazepam | Diazepam | 83 | 15 |
| Simvastatin | Simvastatin | 82 | 24 |
| Alendronate Sodium | Alendronate Sodium | 78 | 26 |
| Prednisone | Prednisone | 78 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 23 |
| Omeprazole | Omeprazole | 61 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 20 |
| Nabumetone | Nabumetone | 58 | 20 |
| Azithromycin | Azithromycin | 57 | 41 |
| Glipizide | Glipizide | 55 | 17 |
| Methylprednisolone | Methylprednisolone | 54 | 39 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 17 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 31 |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Cephalexin | Cephalexin | 47 | 31 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 46 | 13 |
| Lovastatin | Lovastatin | 46 | 15 |
| Meloxicam | Meloxicam | 43 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 16 |
| Celecoxib | Celecoxib | 37 | 12 |
| Montelukast Sodium | Montelukast Sodium | 37 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 14 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | 11 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | 12 |
| Ozempic | Semaglutide | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 18 |
| Eliquis | Apixaban | 30 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Atenolol | Atenolol | 28 | 11 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 18 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 17 |
| Potassium Chloride | Potassium Chloride | 24 | 11 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Aripiprazole Odt | Aripiprazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.27 · 2 records | Amgen Inc. | GEMTESA, REPATHA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Sumitomo Pharma America, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error